Uma Borate, MBBS, discusses reducing treatment toxicity in older patients with AML and the potential for time-limited therapy strategies.
Uma Borate, MBBS, MS
Advertisement
Uma Borate, MBBS, MS, is a physician and professor of hematology in the Department of Internal Medicine at The Ohio State University Comprehensive Cancer Center—James
Articles by Uma Borate, MBBS, MS
Uma Borate, MBBS, MS, discusses results of the OPTI-AML trial comparing 14- and 28-day venetoclax dosing in older adults with acute myeloid leukemia.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5